10 results about "Scutellarin" patented technology

The invention discloses a construction method and application of a scutellaria baicalensis stem and leaf fingerprint spectrum, and belongs to the technical field of medicine quality control. The method comprises the following steps: preparing standard substance solutions of scutellarin, baicalin, taxifolin and isoschaftoside; preparing a scutellaria baicalensis stem and leaf sample solution; detection is carried out under specific conditions through high performance liquid chromatography, a standard fingerprint spectrum of the stems and leaves of scutellaria baicalensis is made by taking a standard chromatographic peak as a reference, and the relative standard deviation of the relative retention time does not exceed + / -20%. The method disclosed by the invention is high in precision, good in stability and excellent in repeatability, effective separation of four flavonoid components can be realized within 35 minutes, and the quality characteristics of stems and leaves of scutellaria baicalensis are comprehensively reflected. The invention further provides application of the fingerprint spectrum in quality analysis of the scutellaria baicalensis stem and leaf medicinal material and the extract thereof, and reliable technical support is provided for resource development and quality control of the scutellaria baicalensis stem and leaf.

The invention relates to a KASP molecular marker associated with scutellarin of erigeron breviscapus and application of the KASP molecular marker, and belongs to the technical field of genetic engineering. The primers of the KASP molecular marker associated with the scutellarin of the erigeron breviscapus comprise a forward primer 1, a forward primer 2 and a common reverse primer; the nucleotide sequence of the forward primer 1 is as shown in SEQ ID NO. 1; the nucleotide sequence of the forward primer 2 is as shown in SEQ ID NO. 2; the nucleotide sequence of the common reverse primer is as shown in SEQ ID NO.3. By utilizing the KASP technology, the SNP site and the corresponding primer combination provided by the invention not only improve the plant variety selection efficiency, but also are beneficial to shortening the breeding cycle and accelerating the cultivation of high-quality plant varieties. The markers have good genetic stability and high resolution, are suitable for high-throughput detection, and have significant application value in the field of plant breeding.

The invention belongs to the field of medicines, and relates to a scutellarin aglycone derivative as well as a preparation method and application thereof. The scutellarin aglycone derivative has a structure as shown in a formula I. The preparation method comprises the following steps: reacting scutellarin (a compound II) with methanol to obtain a compound III, then reacting with bornyl chloroacetate (a compound IV) to obtain a compound V, and finally carrying out an alkaline hydrolysis reaction to obtain the compound I, the scutellarin aglycone derivative has the effect of preventing or treating cardiovascular and cerebrovascular related diseases, can improve the activity of superoxide dismutase (SOD), inhibit the production of lactic dehydrogenase (LDH) and reduce the malondialdehyde (MDA) level superior to that of scutellarin, has the inhibiting effect on inflammatory factors TNF-alpha, IL-6 and IL-1beta in cell supernatant superior to that of scutellarin, and can be used for preparing a medicine for treating cardiovascular and cerebrovascular related diseases, such as cardiovascular and cerebrovascular related diseases, cardiovascular and cerebrovascular related diseases, cardiovascular and cerebrovascular related diseases, cardiovascular and cerebrovascular related diseases, cardiovascular and cerebrovascular related diseases, cardiovascular and cerebrovascular related diseases and cardiovascular and cerebrovascular related diseases. The invention has the potential of preparing or preventing cardiovascular and cerebrovascular related diseases.

This invention provides a method for extracting active ingredients from *Erigeron breviscapus*, belonging to the field of pharmaceutical technology. Based on the differences in the physicochemical properties of the compounds, this invention first achieves preliminary separation of caffeic acid esters and scutellarin, followed by further purification and separation based on the properties of the two types of substances. Specifically, this invention uses ethanol-water solutions of different concentrations to extract caffeic acid esters stepwise, and uses macroporous and microporous resins for preliminary separation of the caffeic acid esters. Scutellarin is then preliminarily separated through acid-base treatment. Finally, high-purity scutellarin, 3,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid, 4,5-dicaffeoylquinic acid, and scutellarin are obtained through reversed-phase industrial chromatography. This invention achieves the extraction and separation of multiple active ingredients from *Erigeron breviscapus*, and all solvents used in the extraction and separation process are recyclable, resulting in low cost.

The invention discloses a recombinant yarrowia lipolytica strain Ylscu-03 for producing scutellarin as well as a construction method and application of the recombinant yarrowia lipolytica strain Ylscu-03, and belongs to the technical field of genetic engineering and metabolic engineering. The recombinant yarrowia lipolytica strain Ylscu-03 is constructed by the following steps: introducing SlA-Tsynth7, SUMO-FNS I-Tsynth27, VPRHX, Pleu-Pxo-Ptef, F7GAT-Tsynth2, UDPGDH-Tsynth8 and TAL-Tsynth7 into a recombinant yarrowia lipolytica engineering strain Ylscu2-00, replacing an original promoter of a yeast endogenous pre-benzoic acid dehydratase gene PHA2 with a core promoter pPHA2-50, and introducing BbXFPK-Tsynth22 and BsPTA-Tsynth7, so that the recombinant yarrowia lipolytica strain Ylscu-03 is obtained. And the yield of scutellarin produced by fermenting Ylscu-03 for 84 hours can reach 6407.63 mg / L.

The invention relates to scutellarin-loaded brain tissue exosome nanoparticles and application thereof in preparation of a medicine for treating diseases by penetrating through a blood brain barrier, and belongs to the technical field of medicines. Brain tissue exosome nanoparticles loaded with scutellarin are added into mouse microglial cells, astrocytes and brain microvascular endothelial cells, so that the nanoparticles can regulate the polarization of the microglial cells caused by PRV infection, remarkably inhibit the expression of M1 type microglial cells CD86, promote the expression of M2 type microglial cells CD 206, inhibit the expression of the PRV infection, and inhibit the PRV infection. The anti-inflammatory effect is achieved; through in-vitro Transwell blood brain barrier and blood brain barrier penetration test of the exosome of a living brain tissue model, it is obtained that the brain tissue exosome can enhance the brain delivery efficiency of scutellarin. The scutellarin-loaded brain tissue exosome nanoparticles provided by the invention solve the problems of difficult scutellarin blood brain barrier penetration and low bioavailability, and have important practical significance in prevention and control of porcine pseudorabies.

The invention belongs to the field of biological medicine, and particularly relates to a scutellarin and luteolin compatible composition and application thereof. In particular discloses a scutellarin and luteolin compatible composition as shown in formulas (I) and (II), and the scutellarin and luteolin compatible composition is applied to treatment and / or prevention of chronic obstructive pulmonary diseases. The screened scutellarin and luteolin compatible composition is simple in preparation method, has a remarkable synergistic treatment effect on the chronic obstructive pulmonary disease, and has a remarkable treatment effect on airway inflammation and lung function impairment of a mouse with the chronic obstructive pulmonary disease induced by a cigarette smoke extract; meanwhile, the composition shows a remarkable inhibiting effect on a neutrophile granulocyte extracellular trap net released by LPS-induced primary mouse bone marrow neutrophile granulocyte, TNF-alpha and IL-6 in vitro, the two medicines have a synergistic effect, the improvement effect is obviously superior to that of a single medicine, and the compatible composition has a relatively high development and application value in treatment of the chronic obstructive pulmonary disease.

This application relates to the field of medicinal chemistry, specifically to a derivative of ligustilide-7-aminocarbamate-4'-substituted aminopropyl ether, its preparation method, and its application. Addressing the shortcomings of ligustilide in AD treatment, this application utilizes previous studies to demonstrate strong eeAChE and huACh inhibitory activity, strong inhibition of self-induction, and Cu... 2+ Induced Aβ 1‑42 Aggregation activity, significantly reduced Aβ 25‑35 The lead compound, scutellarin aglycone-4′-L-amino acid carbamate, which induces tau hyperphosphorylation and significantly improves learning and memory impairment in scopolamine-induced AD model mice, is used to introduce histamine H at the 7-position of its structure. 3 By using the key structural fragment (3-methylpiperidinyl) or cycloheptane group of the receptor antagonist, a cholinesterase inhibitor and histamine H2 receptor antagonist can be obtained. 3 Multi-targeted ligand derivatives with better anti-AD properties through receptor antagonistic synergistic mechanism.

This invention discloses the preparation method and uses of scutellarin 7-phosphate derivatives; belonging to the field of natural medicines and medicinal chemistry. The scutellarin 7-phosphate derivatives and their pharmaceutically acceptable salt structures described in this invention are shown in the following general formula I: By introducing a phosphate group at the 7-position, the scutellarin 7-phosphate derivatives are used in the preparation of drugs for cerebrovascular diseases. They exhibit excellent neuroprotective effects. The scutellarin phosphate derivatives of this invention have good protective activity against H2O2-induced oxidative damage to human neuroblastoma SH-SY5Y cells. Furthermore, the neuroprotective effects of some compounds are significantly stronger than those of the lead compound scutellarin.

The invention relates to a KASP molecular marker associated with erigeron breviscapus erigoster B and application of the KASP molecular marker, and belongs to the technical field of genetic engineering. The primers of the KASP molecular marker associated with Erigeron breviscapus Erigeron ester B comprise a forward primer 1, a forward primer 2 and a common reverse primer; the nucleotide sequence of the forward primer 1 is as shown in SEQ ID NO. 1; the nucleotide sequence of the forward primer 2 is as shown in SEQ ID NO. 2; the nucleotide sequence of the common reverse primer is as shown in SEQ ID NO.3. The SNP site closely related to the content of the erigoster B in the plant is successfully identified through phenotypic difference analysis and re-sequencing technologies, and the medicinal component content of the erigoster B in the plant can be accurately and rapidly evaluated through polymorphic detection of the site.